How Much Muscle Do You Lose on GLP-1 Drugs?
GLP-1 Sarcopenia
25-40% lean mass ratio
In clinical trials, 25-40% of total weight lost on GLP-1 receptor agonists came from lean mass rather than fat, measured by DEXA.
Pantazopoulos et al., Diabetes Res Clin Pract, 2025
Pantazopoulos et al., Diabetes Res Clin Pract, 2025
View as imageEvery diet causes some lean mass loss. When your body burns more calories than it takes in, it does not exclusively target fat stores. Some muscle protein is broken down for energy, water bound to glycogen is released, and organ tissue adjusts to the reduced metabolic demand. The question with GLP-1 receptor agonists is whether the lean mass loss is disproportionate, clinically concerning, or different from what you would expect with equivalent weight loss through diet and exercise alone. The trial data, measured primarily with DEXA scans, gives a clear numerical answer. For broader context on this issue in older adults, see our pillar article on GLP-1 weight loss and sarcopenia.
Key Takeaways
- In the STEP 1 DEXA substudy, approximately 39% of semaglutide-induced weight loss came from lean mass, with fat mass accounting for the remaining 61%
- The SEMALEAN study (2026) found semaglutide 2.4mg reduced lean body mass but generally preserved handgrip strength through 12 months[1]
- Higher semaglutide doses predicted greater muscle mass loss in a 24-month retrospective cohort of older adults with type 2 diabetes[2]
- Tirzepatide reduced thigh muscle fat infiltration more than expected from weight loss alone, suggesting qualitative muscle improvement despite volume loss[3]
- The lean mass loss ratio (25-40%) is consistent with what's observed in caloric restriction studies of similar magnitude, not unique to GLP-1 drugs[4]
The Numbers: What DEXA Scans Show
DEXA (dual-energy X-ray absorptiometry) measures total body composition by distinguishing fat mass, lean soft tissue mass, and bone mineral content. Several GLP-1 receptor agonist trials have included DEXA substudies, giving precise body composition data rather than just scale weight.
STEP 1 Body Composition
The STEP 1 trial randomized adults with obesity to semaglutide 2.4mg or placebo for 68 weeks. A DEXA substudy of 140 participants measured body composition changes. Semaglutide produced an average weight loss of approximately 15%. Of that total weight loss:
- Fat mass decreased by 19.3% from baseline
- Lean body mass decreased by 9.7% from baseline
- Visceral fat mass decreased by 27.4% from baseline
The lean mass loss as a proportion of total weight loss was approximately 39%. However, because more fat was lost than lean tissue in absolute terms, the proportion of lean mass relative to total body mass actually increased by 3.0 percentage points. In other words, patients ended up with a higher lean-to-fat ratio despite losing some lean tissue.
The SEMALEAN Study
Alissou and colleagues published the SEMALEAN study in 2026, following 106 patients on semaglutide 2.4mg for up to 12 months with detailed body composition and muscle function assessments.[1] Mean weight reduction was 10% at 7 months and 13% at 12 months. The study confirmed reduced lean body mass alongside the fat loss. The key finding: handgrip strength was generally preserved throughout the 12-month treatment period. This suggests that while total lean mass decreased on the scale and DEXA scan, functional muscle capacity was maintained.
This distinction between mass and function is critical. Lean mass on a DEXA scan includes muscle, but also organ tissue, water, and connective tissue. A person who loses 30 pounds does not need the same size liver, the same volume of blood, or the same amount of interstitial fluid as when they were 30 pounds heavier. Some lean mass loss during weight reduction reflects normal physiological downsizing of organs and support structures to match a smaller body, not muscle wasting. A 200-pound person has more lean mass than a 170-pound person even if they have identical muscle development, because the larger body requires more metabolically active organ tissue to maintain.
This is why the lean mass percentage of weight loss (25-40%) can be misleading if interpreted as pure muscle loss. The actual skeletal muscle loss is likely a fraction of the total lean mass reduction, with the remainder coming from organ downsizing, fluid shifts, and glycogen-associated water loss.
Tirzepatide Data
Tirzepatide, a dual GLP-1/GIP receptor agonist, has its own body composition data. The SURMOUNT-1 DEXA substudy showed body composition changes during weight reduction with tirzepatide in adults with obesity.[5]
Sattar and colleagues analyzed the SURPASS-3 MRI substudy, which provided detailed muscle imaging data.[3] Tirzepatide reduced thigh muscle volume proportionally to overall weight loss, which was expected. But it also reduced intramuscular fat infiltration more than predicted from the weight loss alone. Fatty infiltration of muscle (myosteatosis) impairs muscle quality and function independent of muscle size. By reducing this infiltration, tirzepatide may improve muscle quality even while muscle volume decreases.
Rochira and colleagues conducted a systematic review of tirzepatide's effects on body composition and concluded that while fat mass consistently decreased, the ratio of fat to lean mass loss varies across studies and requires clinical attention.[6]
Is This More Muscle Loss Than Normal Dieting?
The critical comparison is not GLP-1 drugs versus no weight loss. It is GLP-1 drugs versus equivalent weight loss through other means. When researchers compare the lean mass loss ratio (proportion of total weight lost that comes from lean tissue) across different weight loss interventions, a consistent pattern emerges.
Bhandarkar and colleagues reviewed the body composition effects of GLP-1 receptor agonists and found that the lean mass percentage of total weight loss falls within the range observed in dietary intervention studies of similar magnitude.[4] Caloric restriction studies typically report 20-40% of weight loss as lean mass, depending on the rate of weight loss, protein intake, and exercise status. GLP-1 agonist trials report 25-40%, overlapping substantially with this range.
Jamialahmadi and colleagues reviewed the semaglutide lean mass data specifically and reached a similar conclusion: semaglutide-induced lean mass loss is proportional to the degree of weight loss, not disproportionate to it.[7]
This does not mean the lean mass loss is irrelevant. It means GLP-1 drugs do not appear to cause muscle-specific wasting beyond what any equivalent caloric deficit would produce. The concern is not that these drugs are uniquely muscle-toxic. The concern is that rapid, substantial weight loss from any cause carries lean mass costs, and GLP-1 drugs produce rapid, substantial weight loss very effectively. A person losing 15-20% of their body weight over 68 weeks on semaglutide is experiencing a caloric deficit that would cause comparable lean mass loss whether achieved through drug-induced appetite suppression, surgical intervention, or dietary restriction. The rate and magnitude of weight loss, not the mechanism by which appetite is suppressed, appears to be the primary determinant of how much lean tissue is lost. Slower weight loss and higher protein intake consistently reduce the lean mass proportion in dietary studies, and the same principles likely apply to pharmacological weight loss.
The Sarcopenia Risk in Older Adults
The population where lean mass loss matters most is older adults who already have low muscle reserves. Pantazopoulos and colleagues published a narrative review specifically addressing the sarcopenia risk from GLP-1 receptor agonists.[8] Their analysis highlighted a paradox: clinical studies show GLP-1RAs can cause significant lean mass loss and sarcopenia risk in patients, while preclinical studies paradoxically show these agents may attenuate skeletal muscle atrophy, improve muscle function, and enhance mitochondrial efficiency in animal models.
Ren and colleagues provided the most concerning long-term data. Their 24-month retrospective cohort study followed older adults with type 2 diabetes on semaglutide therapy.[2] Semaglutide reduced both BMI and muscle mass over 24 months. Grip strength initially improved then declined in men, while gait speed decreased in both sexes. Higher doses predicted greater muscle loss. This suggests that in older adults, the initial metabolic benefits of weight loss may be offset by progressive muscle deterioration with continued use.
For older adults already near the sarcopenia threshold (low muscle mass, declining strength, reduced physical function), losing an additional 25-40% of their weight loss from lean tissue could push them below functional thresholds that increase fall risk, disability, and mortality. For more on this risk, see our article on GLP-1s and bone density.
Muscle Quality vs Muscle Quantity
The SURPASS-3 MRI data introduced an important nuance. Sattar and colleagues showed that tirzepatide reduced intramuscular fat infiltration beyond what weight loss alone would predict.[3] Fatty infiltration of muscle (myosteatosis) is independently associated with insulin resistance, reduced muscle strength per unit of muscle area, and worse physical function in older adults.
If GLP-1/GIP agonists improve muscle quality by reducing intramuscular fat even while reducing total muscle volume, the net functional effect could be neutral or even positive. This would explain the SEMALEAN finding that grip strength was preserved despite lean mass reduction.[1] A smaller but less fatty muscle may perform as well as or better than a larger but fattier one.
Ditzenberger and colleagues examined semaglutide's effects on muscle structure and function in the SLIM LIVER study and provided additional data on this quality versus quantity distinction.[9] The interplay between reduced muscle volume and improved muscle composition is an active area of research that simple DEXA measurements cannot capture.
Can You Prevent the Muscle Loss?
Two modifiable factors have the strongest evidence for mitigating lean mass loss during GLP-1 therapy: resistance training and protein intake. Both are addressed in dedicated articles in this cluster.
The physiological rationale is straightforward: resistance training provides a mechanical stimulus that signals the body to preserve or build muscle tissue even during caloric deficit. Adequate protein intake (1.2-1.6 g/kg/day or higher) provides the amino acid substrate needed for muscle protein synthesis. When combined, these interventions consistently reduce the lean mass proportion of weight loss in dietary studies. Whether they fully counteract lean mass loss during GLP-1 therapy is being tested in ongoing trials. For details, see our articles on resistance training on semaglutide and protein intake on GLP-1s.
For a detailed comparison of semaglutide's fat-versus-muscle effects, see our cross-cluster article on semaglutide body composition. For the broader cosmetic and structural effects, see our article on Ozempic face and muscle effects.
What Remains Unknown
The longest published body composition data for GLP-1 drugs extends to 24 months. Whether lean mass loss stabilizes, reverses, or continues beyond two years of treatment is unknown. Given that many patients are expected to remain on GLP-1 therapy indefinitely, this is a significant gap.
No large randomized trial has directly compared lean mass outcomes between GLP-1-induced weight loss and matched caloric restriction with the same total weight loss. The "normal range" comparisons referenced above are cross-study comparisons, not head-to-head data.
The COURAGE trial (Regeneron) is specifically designed to test whether adding trevogrumab (an anti-activin receptor antibody) to semaglutide can preserve lean mass during weight loss. Interim results suggested approximately 35% of semaglutide-induced weight loss was lean mass, and trevogrumab reduced this proportion. Full results will better define the problem and potential solutions.
DEXA does not distinguish between muscle tissue and other lean soft tissue (organ mass, water, connective tissue). MRI-based studies like SURPASS-3 provide better muscle-specific data but are available for fewer trials. The true muscle-specific loss may be lower than the total lean mass loss reported by DEXA.
There is also the rebound question: what happens to body composition when GLP-1 drugs are discontinued? The STEP 1 extension data showed weight regain after semaglutide discontinuation, but the composition of regained weight (fat versus lean mass) has not been fully characterized. If regained weight is disproportionately fat, patients could end up with worse body composition than before treatment, a phenomenon sometimes called "fat overshooting" that has been observed after conventional dieting.
The Bottom Line
Clinical trial DEXA data shows that 25-40% of weight lost on GLP-1 receptor agonists comes from lean mass, with the remainder from fat. This ratio is consistent with what's observed in caloric restriction studies of similar magnitude, suggesting GLP-1 drugs do not cause disproportionate muscle wasting. However, the absolute lean mass loss is clinically relevant, particularly in older adults near sarcopenia thresholds, where a 24-month study found higher doses predicted greater muscle loss and declining physical function. Newer MRI data from tirzepatide trials shows reduced intramuscular fat infiltration, suggesting muscle quality may improve even as quantity decreases. Grip strength was preserved in the 12-month SEMALEAN study despite measurable lean mass reduction.